No more insulin injections for diabetes patients? UAE doctors explain cell-based treatment
Many diabetic patients abroad have said goodbye to insulin injections or now use them less frequently and in lower doses, according to doctors who noted patients recovered after undergoing a simple surgical procedure to transplant pancreatic cells.
"50 per cent of patients with Type 1 diabetes — who typically rely on insulin injections — have been cured through 'islet cell transplantation'," Dr Tahra Abdalla Al Ali, a pediatrician based in the UAE, told Khaleej Times.
"This has cured people of their pancreas's inability to produce insulin. Patients will no longer depend on insulin as they look forward to a future without constant insulin management.'
Dr Al Ali noted, 'In 25 cases, pancreatic cells were transplanted; and the success rate for this group was 85 per cent. Of the patients, 50 per cent completely stopped using medication. The remaining group members use injections at lower doses and less frequently.'
Stay up to date with the latest news. Follow KT on WhatsApp Channels.
This treatment, which aims to benefit all patient groups, initially targeted individuals over the age of 20 who suffered from complications of diabetes and had difficulty maintaining healthy levels for an extended period.
Procedure explained
Dr Al Ali said islet cell transplantation involves transplanting pancreatic cells extracted from donors and studying them in specialised laboratories. Once the safety of these samples is confirmed, they are injected into the patient using a catheter-like method through the skin into a vein and then transplanted onto the liver.
'The transplanted cells help restore and regulate blood sugar levels in patients with type 1 diabetes, preventing severe, life-threatening hypoglycemia episodes and allowing patients to eliminate their daily insulin injections,' she added.
Simple and safe
The procedure is considered an alternative to the complete pancreas transplant to avoid surgical complications, including organ rejection and bleeding. It is regarded as a safe and simple treatment method.
The Emirates Health Services (EHS), in collaboration with the University of Chicago, is working to treat patients from the UAE either abroad or by bringing experts to the country to provide care.
Only for Type 1 diabetes
The procedure is used exclusively for patients with Type 1 diabetes, where the main issue is the destruction of insulin-producing beta cells, Dr Patanjali Panduranga, endocrinologist at Aster Hospital, explained. It is not considered a treatment for Type 2 diabetes, where insulin resistance is the primary problem. However, some early studies are exploring its use in selected cases of insulin-dependent type 2 diabetes, although this remains under investigation.
He noted the US Food and Drug Administration (FDA) approved islet cell transplantation in 2023 for adults with Type 1 diabetes who experienced severe hypoglycemia or poor glucose control despite intensive insulin therapy.
Limitations remain
'Although the procedure has shown promising results, including insulin independence in up to 50 per cent of recipients, its broader clinical use remains limited due to the need for lifelong immunosuppression and the scarcity of suitable donor cells,' said Dr Panduranga.
Dr Arvind Gaddameedi, another endocrinologist at Aster Clinic, explained that the success of islet cell transplantation depends on two key factors, safety and sustainability. Unlike full organ transplants, this procedure involves a 30-minute infusion under local anesthesia, making it accessible even to high-risk patients. However, challenges remain.
One of the challenges is the availability of donor cells. While organ donation rates vary globally, innovations in islet cell processing, cryopreservation, and even stem cell-derived islets, currently under trial, may soon expand accessibility.
'These developments represent a new dawn in diabetes care. While not yet a first-line treatment, islet cell transplantation is a vital option for patients struggling with the demands of insulin therapy. As research progresses, improvements in immunosuppression, donor matching, and cell supply are expected to make this treatment more widely available.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
5 hours ago
- Khaleej Times
No more insulin injections for diabetes patients? UAE doctors explain cell-based treatment
Many diabetic patients abroad have said goodbye to insulin injections or now use them less frequently and in lower doses, according to doctors who noted patients recovered after undergoing a simple surgical procedure to transplant pancreatic cells. "50 per cent of patients with Type 1 diabetes — who typically rely on insulin injections — have been cured through 'islet cell transplantation'," Dr Tahra Abdalla Al Ali, a pediatrician based in the UAE, told Khaleej Times. "This has cured people of their pancreas's inability to produce insulin. Patients will no longer depend on insulin as they look forward to a future without constant insulin management.' Dr Al Ali noted, 'In 25 cases, pancreatic cells were transplanted; and the success rate for this group was 85 per cent. Of the patients, 50 per cent completely stopped using medication. The remaining group members use injections at lower doses and less frequently.' Stay up to date with the latest news. Follow KT on WhatsApp Channels. This treatment, which aims to benefit all patient groups, initially targeted individuals over the age of 20 who suffered from complications of diabetes and had difficulty maintaining healthy levels for an extended period. Procedure explained Dr Al Ali said islet cell transplantation involves transplanting pancreatic cells extracted from donors and studying them in specialised laboratories. Once the safety of these samples is confirmed, they are injected into the patient using a catheter-like method through the skin into a vein and then transplanted onto the liver. 'The transplanted cells help restore and regulate blood sugar levels in patients with type 1 diabetes, preventing severe, life-threatening hypoglycemia episodes and allowing patients to eliminate their daily insulin injections,' she added. Simple and safe The procedure is considered an alternative to the complete pancreas transplant to avoid surgical complications, including organ rejection and bleeding. It is regarded as a safe and simple treatment method. The Emirates Health Services (EHS), in collaboration with the University of Chicago, is working to treat patients from the UAE either abroad or by bringing experts to the country to provide care. Only for Type 1 diabetes The procedure is used exclusively for patients with Type 1 diabetes, where the main issue is the destruction of insulin-producing beta cells, Dr Patanjali Panduranga, endocrinologist at Aster Hospital, explained. It is not considered a treatment for Type 2 diabetes, where insulin resistance is the primary problem. However, some early studies are exploring its use in selected cases of insulin-dependent type 2 diabetes, although this remains under investigation. He noted the US Food and Drug Administration (FDA) approved islet cell transplantation in 2023 for adults with Type 1 diabetes who experienced severe hypoglycemia or poor glucose control despite intensive insulin therapy. Limitations remain 'Although the procedure has shown promising results, including insulin independence in up to 50 per cent of recipients, its broader clinical use remains limited due to the need for lifelong immunosuppression and the scarcity of suitable donor cells,' said Dr Panduranga. Dr Arvind Gaddameedi, another endocrinologist at Aster Clinic, explained that the success of islet cell transplantation depends on two key factors, safety and sustainability. Unlike full organ transplants, this procedure involves a 30-minute infusion under local anesthesia, making it accessible even to high-risk patients. However, challenges remain. One of the challenges is the availability of donor cells. While organ donation rates vary globally, innovations in islet cell processing, cryopreservation, and even stem cell-derived islets, currently under trial, may soon expand accessibility. 'These developments represent a new dawn in diabetes care. While not yet a first-line treatment, islet cell transplantation is a vital option for patients struggling with the demands of insulin therapy. As research progresses, improvements in immunosuppression, donor matching, and cell supply are expected to make this treatment more widely available.'
Khaleej Times
11 hours ago
- Khaleej Times
Iran says at least 13 nationals die during Hajj pilgrimage
At least 13 Iranian nationals died while performing the Hajj pilgrimage in Saudi Arabia amid rising temperatures in the holy cities, Iranian state media reported Saturday. "As of Friday, June 6, the total number of Iranian pilgrims who have passed away during Hajj 2025 has reached 13," the health and treatment operations unit of Iranian Red Crescent Society said in a statement carried by the official IRNA news agency. The statement did not specify the cause of deaths but cautioned the pilgrims to avoid direct exposure to the sun and drink plenty of water among other things to reduce the risk of heatstroke. "In recent days, temperatures in the holy cities of Saudi Arabia have risen to 47°C, which can lead to severe heatstroke among pilgrims," IRNA said, adding that 86,700 Iranians went to Saudi Arabia this year for the pilgrimage. Last year, more than 1,300 people - including 22 Iranians - died at the Hajj pilgrimage in Saudi Arabia where temperatures hit 51.8C (125 degrees Fahrenheit). Heat stress occurs when the body's natural cooling systems are overwhelmed, causing symptoms ranging from dizziness and headaches to organ failure and death. The statement on Saturday also advised pilgrims to avoid direct sun exposure, stay hydrated and take other precautions to reduce the risk of heatstroke. Climate change is driving an increasing number of deadly heatwaves across the globe with the World Health Organisation estimating that heat kills at least half a million people every year, warning that the real figure could be up to 30 times higher.
Zawya
a day ago
- Zawya
IntelliDent AI and Woxsen University forge strategic alliance to advance AI research, leadership & innovation in healthcare
IntelliDent AI, a Dubai-based healthtech company at the forefront of artificial intelligence solutions in dentistry, has signed a Memorandum of Understanding (MoU) with Woxsen University's AI Research Centre, Hyderabad, India. The five-year strategic partnership aims to drive collaborative innovation through joint research, live project exposure, and advanced technical training. This collaboration is designed to fuel co-innovation, AI-driven entrepreneurship, and cutting-edge research in digital healthcare. Under this agreement, IntelliDent AI and Woxsen University will engage in joint academic-industry initiatives focused on AI-driven healthcare solutions, consultancy-based projects, and the commercialization of technology innovations. The MoU outlines cooperation in the following key areas: Real-World AI Projects: IntelliDent will provide students from Woxsen's AI Research Centre hands-on exposure to live, real-time projects from the healthcare domain—preparing them to address real-world challenges with AI-driven solutions. Joint Research & Publications: Both institutions will collaborate on research grants, white papers, product prototypes, and academic publications that shape the future of medical technology. Entrepreneurship & Product Commercialization: Special focus will be placed on developing products from ideation to market readiness, with guidance on building startups and commercializing AI health tech solutions. Cross-Training & Knowledge Exchange: Faculty and industry professionals will exchange expertise in best practices, fostering a culture of mutual growth and continuous innovation. Strategic Awareness Initiatives: Co-hosted awareness programs, leadership bootcamps, and innovation challenges will promote ethical AI, responsible leadership, and entrepreneurship across emerging markets. Speaking on the occasion, Mr. Affaan Shaikh, Founder and CEO of IntelliDent AI, stated: 'This MoU with Woxsen isn't just about technology, it's about inspiring a generation of AI leaders who blend deep tech knowledge with entrepreneurial thinking and purpose-driven leadership. By embedding awareness, education, and innovation into every layer of this partnership, we are not only building smarter healthcare systems, but also empowering future changemakers.' The MoU was signed by Dr. Raul V. Rodriguez, Vice President of Woxsen University, and Mr. Affaan Shaikh, with oversight by Dr. Hemachandran K, Director of the AI Research Centre, and Mr. Khalid Shaikh, Advisor to IntelliDent AI. This milestone underscores IntelliDent AI's commitment to shaping global talent in healthcare AI and highlights Woxsen's ongoing mission to blend business, technology, and innovation through meaningful industry collaborations. Together, IntelliDent AI and Woxsen University are setting the foundation for impactful, future-forward education —where research, leadership, and real-world problem-solving converge.
